Corcept Therapeutics (CORT) Tops Q3 EPS by 3c

November 1, 2016 5:52 PM EDT

Get access to the best calls on Wall Street with StreetInsider.com's Ratings Insider Elite. Get your Free Trial here.

Corcept Therapeutics (NASDAQ: CORT) reported Q3 EPS of $0.04, $0.03 better than the analyst estimate of $0.01. Revenue for the quarter came in at $21.7 million versus the consensus estimate of $21.24 million.

GUIDANCE:

Corcept Therapeutics sees Q4 2016 revenue of $79-82 million, versus the consensus of $80.3 million.

For earnings history and earnings-related data on Corcept Therapeutics (CORT) click here.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In






Related Categories

Earnings, Guidance

Related Entities

Earnings

Add Your Comment